203 related articles for article (PubMed ID: 19689255)
1. Histone deacetylase inhibitors target diabetes via chromatin remodeling or as chemical chaperones?
Lawless MW; O'Byrne KJ; Gray SG
Curr Diabetes Rev; 2009 Aug; 5(3):201-9. PubMed ID: 19689255
[TBL] [Abstract][Full Text] [Related]
2. Targeting histone deacetylases for the treatment of disease.
Lawless MW; Norris S; O'Byrne KJ; Gray SG
J Cell Mol Med; 2009 May; 13(5):826-52. PubMed ID: 19175682
[TBL] [Abstract][Full Text] [Related]
3. Role of histone and transcription factor acetylation in diabetes pathogenesis.
Gray SG; De Meyts P
Diabetes Metab Res Rev; 2005; 21(5):416-33. PubMed ID: 15906405
[TBL] [Abstract][Full Text] [Related]
4. Targeting histone deacetylases for the treatment of immune, endocrine & metabolic disorders.
Lawless MW; Norris S; O'Byrne KJ; Gray SG
Endocr Metab Immune Disord Drug Targets; 2009 Mar; 9(1):84-107. PubMed ID: 19275684
[TBL] [Abstract][Full Text] [Related]
5. Lysine acetylation in obesity, diabetes and metabolic disease.
Iyer A; Fairlie DP; Brown L
Immunol Cell Biol; 2012 Jan; 90(1):39-46. PubMed ID: 22083525
[TBL] [Abstract][Full Text] [Related]
6. Histone deacetylase inhibitors in cancer therapy: latest developments, trends and medicinal chemistry perspective.
Balakin KV; Ivanenkov YA; Kiselyov AS; Tkachenko SE
Anticancer Agents Med Chem; 2007 Sep; 7(5):576-92. PubMed ID: 17896917
[TBL] [Abstract][Full Text] [Related]
7. Acetylation of proteins as novel target for antitumor therapy: review article.
Di Gennaro E; Bruzzese F; Caraglia M; Abruzzese A; Budillon A
Amino Acids; 2004 Jul; 26(4):435-41. PubMed ID: 15290351
[TBL] [Abstract][Full Text] [Related]
8. Prospects: histone deacetylase inhibitors.
Dokmanovic M; Marks PA
J Cell Biochem; 2005 Oct; 96(2):293-304. PubMed ID: 16088937
[TBL] [Abstract][Full Text] [Related]
9. Histone deacetylase inhibitors: molecular and biological activity as a premise to clinical application.
Santini V; Gozzini A; Ferrari G
Curr Drug Metab; 2007 May; 8(4):383-93. PubMed ID: 17504226
[TBL] [Abstract][Full Text] [Related]
10. [Assay for inhibitory activity of histone deacetylase].
Yoshida M
Gan To Kagaku Ryoho; 2004 Apr; 31(4):507-11. PubMed ID: 15114691
[TBL] [Abstract][Full Text] [Related]
11. HDACs and HDAC Inhibitors in Cancer Development and Therapy.
Li Y; Seto E
Cold Spring Harb Perspect Med; 2016 Oct; 6(10):. PubMed ID: 27599530
[TBL] [Abstract][Full Text] [Related]
12. Histone deacetylases: unique players in shaping the epigenetic histone code.
Thiagalingam S; Cheng KH; Lee HJ; Mineva N; Thiagalingam A; Ponte JF
Ann N Y Acad Sci; 2003 Mar; 983():84-100. PubMed ID: 12724214
[TBL] [Abstract][Full Text] [Related]
13. Histone deacetylase inhibitors.
Marks PA; Richon VM; Miller T; Kelly WK
Adv Cancer Res; 2004; 91():137-68. PubMed ID: 15327890
[TBL] [Abstract][Full Text] [Related]
14. Remodeling chromatin and stress resistance in the central nervous system: histone deacetylase inhibitors as novel and broadly effective neuroprotective agents.
Langley B; Gensert JM; Beal MF; Ratan RR
Curr Drug Targets CNS Neurol Disord; 2005 Feb; 4(1):41-50. PubMed ID: 15723612
[TBL] [Abstract][Full Text] [Related]
15. Chromatin regulation in schistosomes and histone modifying enzymes as drug targets.
Pierce RJ; Dubois-Abdesselem F; Caby S; Trolet J; Lancelot J; Oger F; Bertheaume N; Roger E
Mem Inst Oswaldo Cruz; 2011 Nov; 106(7):794-801. PubMed ID: 22124550
[TBL] [Abstract][Full Text] [Related]
16. The structure and function of histone deacetylases: the target for anti-cancer therapy.
Zhang Y; Fang H; Jiao J; Xu W
Curr Med Chem; 2008; 15(27):2840-9. PubMed ID: 18991639
[TBL] [Abstract][Full Text] [Related]
17. Histone deacetylase inhibitors as antidiabetic agents: Advances and opportunities.
Sonthalia M; Roy BS; Chandrawanshi D; Ganesh GV; Jayasuriya R; Mohandas S; Rajagopal S; Ramkumar KM
Eur J Pharmacol; 2022 Nov; 935():175328. PubMed ID: 36257383
[TBL] [Abstract][Full Text] [Related]
18. Histone deacetylase inhibitors: a new wave of molecular targeted anticancer agents.
Budillon A; Di Gennaro E; Bruzzese F; Rocco M; Manzo G; Caraglia M
Recent Pat Anticancer Drug Discov; 2007 Jun; 2(2):119-34. PubMed ID: 18221057
[TBL] [Abstract][Full Text] [Related]
19. Focus on acetylation: the role of histone deacetylase inhibitors in cancer therapy and beyond.
Konstantinopoulos PA; Karamouzis MV; Papavassiliou AG
Expert Opin Investig Drugs; 2007 May; 16(5):569-71. PubMed ID: 17461732
[TBL] [Abstract][Full Text] [Related]
20. Nuclear histone acetylases and deacetylases and transcriptional regulation: HATs off to HDACs.
Hassig CA; Schreiber SL
Curr Opin Chem Biol; 1997 Oct; 1(3):300-8. PubMed ID: 9667866
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
